Novoprotein Scientific Inc (688137) Fair Value & Analysis
Healthcare · CN · Market cap 2.6B CNY
Fair value as of: Jul 12, 2026
From 3 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from ¥130.48 to ¥24.77 (−81.0%) since Jun 24, 2026. Share price +3.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥33.67 – ¥53.88 · fair‑value band ¥16.35 – ¥30.96 · the ¥39.00 price screens above the ¥24.77 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Novoprotein Scientific Inc (688137) currently trades at ¥39.00, while our model-based Fair Value estimate is ¥24.77 — implying the stock looks roughly 36.5% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Novoprotein Scientific Inc generated revenue of 150M CNY at a net margin of -51.0%. Revenue grew 11.4% year over year. It earns a return on equity of -3.7%. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥16.35 (bear case) to ¥30.96 (bull case); at ¥39.00, the current price sits above that range. The share trades about 29% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -36%, 688137 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, enzymes and reagents, biosimilar reference antibodies, gene and cell therapy, molecular research and diagnosis, and virus-related products, including antigens, antibodies and test kits. The company also provides protein expression and purification; industrial strain and process development; antibody development and production service; antibody screening and optimization services; and IVT mRNA/circRNA /SaRNA production services. It offers its products and services in the fields of biopharmaceuticals, mRNA vaccines and drugs, in vitro diagnostics, biological drugs, basic research of life sciences, and other areas. The company was founded in 2009 and is headquartered in Suzhou, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Novoprotein Scientific Inc reported revenue of ¥146M in FY2025 versus ¥342M in FY2021, a compound −19.1%/yr. Reported net income was −¥77.8M in FY2025.
Is 688137 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novoprotein Scientific Inc (688137) undervalued?
What is the fair value of 688137?
What is the quality score of 688137?
What is the revenue of Novoprotein Scientific Inc (688137)?
What is the net profit margin of 688137?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Novoprotein Scientific Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.